As Patents Expire, Oncology Biosimilars Poised to Expand, Authors Say
(The Center For Biosimilars) Feb 11, 2020 - By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article. READ ARTICLE